• Journal of Applied Biological Chemistry
• /
• v.65 no.1
• /
• pp.75-79
• /
• 2022

Antioxidant, α-glucosidase inhibition, and anticoagulant effects of 80% ethanolic extract from mistletoe (Viscum album var. coloratum) were investigated. The yield and polyphenol content of the mistletoe extract were 30.9±0.4% and 57.6±1.5 mg gallic acid equivalents/g, respectively. The antioxidant effects of the mistletoe extract such as free and cationic radical scavenging ability, nitrite scavenging ability, and reducing power increased in proportion to its concentration. Also the mistletoe extract inhibited the activity of α-glucosidase, and delayed plasma coagulation mainly by inhibiting the extrinsic and common pathways in blood coagulation system.

• Childhood Kidney Diseases
• /
• v.28 no.2
• /
• pp.80-85
• /
• 2024

Lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) is a rare entity characterized by the presence of lupus anticoagulant (LA) and prothrombin (factor II) deficiency. It may cause severe bleeding contrary to classical antiphospholipid syndrome. Here, we report a case of LAHPS presenting with a hemorrhagic ovarian cyst in a 17-year-old girl with systemic lupus erythematosus (SLE) nephritis. She had been followed up for 8 years. Her first manifestation of SLE was prolonged gingival bleeding after tooth extraction at 9 years of age. During the follow-up period, she had neither severe bleeding nor thrombotic complications despite a positive LA and a prolonged activated partial thromboplastin time (aPTT). At this visit, the patient presented with colicky abdominal pain, a hemorrhagic ovarian cyst, a prolonged prothrombin time, a prolonged aPTT, a low factor II level, and a positive LA, leading to the diagnosis of LAHPS. While a hemorrhagic ovarian cyst resolved completely in 3 months, she received oral pill, transfusions of red blood cells and plasma, and intravenous cyclophosphamide pulse therapy in combination with glucocorticoids due to persistent menorrhagia, anemia, prolonged aPTT, and lupus flaring. Thus, LAHPS needs to be considered in SLE patients with positive LA and prolonged aPTT.

• Childhood Kidney Diseases
• /
• v.18 no.2
• /
• pp.98-105
• /
• 2014

Purpose: Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been investigated as an anticoagulant for adult patients with a high risk of bleeding, who need chronic renal replacement therapy (CRRT). However, little is known about the use of NM as an anticoagulant in pediatric CRRT. The aim of this study was to evaluate the ideal dosage, efficacy, and safety of NM in pediatric CRRT. Methods: We conducted a retrospective study of 40 pediatric patients who had undergone at least 24 h of venovenous CRRTs between January 2011 and October 2013. We divided the patients according to risk of bleeding. Those at high risk received no anticoagulation (group 1) or NM as an anticoagulant (group 2), while those at low risk received heparin (group 3). Results: Forty patients (25 male and 15 female; mean age, $8.2{\pm}6.6$ years) were enrolled. The mean duration of CRRT was 13.0 days, and the survival rate was 57.5%. The mean hemofilter lifespan was 39.3 h in group 1 and 11.3 h in group 3. In group 2, hemofilter lifespan was extended from 7.5 h to 27.4 h after the use of NM (P =0.001). The mean hemofilter lifespan with NM was greater than with heparin (P =0.018). No patient experienced a major bleeding event during treatment with NM. Conclusion: NM may be a good alternative anticoagulant in pediatric patients with a high risk of bleeding requiring CRRT, and is not associated with bleeding complications.

• Proceedings of the Korea Crystallographic Association Conference
• /
• 2005.11a
• /
• pp.11-11
• /
• 2005

• Journal of Gastric Cancer
• /
• v.22 no.1
• /
• pp.1-2
• /
• 2022

• Journal of Pharmacopuncture
• /
• v.23 no.3
• /
• pp.179-179
• /
• 2020

• Journal of Microbiology and Biotechnology
• /
• v.3 no.2
• /
• pp.65-72
• /
• 1993

A heterologous gene expression and secretion system using a methylotrophic yeast, Hansenula polymorpha was developed for the production of anticoagulant hirudin. Hirudin gene was expressed under the control of a strong and inducible methanol oxidase (MOX or AOX) promoter. The mating factor a pre-pro leader sequence of Saccharomyces cerevisiae was employed for hirudin to be secreted into the extracellular medium. Hirudin expression cassette was introduced into three strains of H. polymorpha, A16, HPBl and DLl which have different genetic backgrounds. This expression cassette was stably integrated into the host chromosomal DNA. Biologically active and mature hirudin was efficiently expressed and secreted into the extracellular medium. About 19 mg/L of hirudin was found in the culture supernatant in the case of a two-copy integrant of the strain HPBl under suboptimal culture conditions.

• Food Science and Biotechnology
• /
• v.15 no.5
• /
• pp.763-767
• /
• 2006

The anticoagulant properties of compounds derived from fennel (Foeniculum vulgare Gaertner) fruits were evaluated using a platelet aggregometer and compared with aspirin. The active constituents of fennel fruits were isolated and identified as (+)-fenchone and extragole by various spectral analysis techniques. With regard to the 50% inhibitory concentration ($IC_{50}$), (+)-fenchone effectively inhibited platelet aggregation induced by treatment with collagen ($IC_{50}$, $3.9\;{\mu}M$) and arachidonic acid (AA) ($IC_{50}$, $27.1\;{\mu}M$), and estragole inhibited collagen-induced platelet aggregation ($IC_{50}$, $4.7\;{\mu}M$). By way of comparison, (+)-fenchone and estragole proved to be significantly more potent than aspirin at inhibiting platelet aggregation induced by collagen. The inhibitory activity of (+)-fenchone toward platelet aggregation induced by AA was 1.3 times stronger than that of aspirin. These results indicate that (+)- fenchone and estragole may be useful as lead compounds for inhibiting platelet aggregation induced by arachidonic acid and collagen.

• Korean Journal of Agricultural Science
• /
• v.24 no.1
• /
• pp.55-62
• /
• 1997

Hirudin is a potent thrombin inhibitor originally derived from the medicinal leech. Leeches were commonly used at the turn of the century for bloodletting and are still used today in some countries. So, hirudin is being developed as a alternative to heparin which has several shortcomings. This study is intended to analyze R&D trends, potential market for hirudin and existing anticoagulant drug market. Anticoagulant drug market in Korea is estimated by over 1,200 billion won in 2010 and revenues in the world market are forecasted to reach 1.62 billion dollar in 1999.

• Biomolecules & Therapeutics
• /
• v.1 no.2
• /
• pp.166-170
• /
• 1993

Hirudin is a potent inhibitor of thrombin, which was originally obtained from the medicinal leech (Hirudo medicinalis) Now it is being produced through the recombinant technology on a large scale. Recombinant hirudin has been assayed for the anticoagulant activity by the measurement of clotting time and the inhibition of thrombin actvity using a chromogenic substrate. The assay range of partial thromboplastin time and thrombin time is within $0.2{\sim}1.0 {\mu}g/mι.$ Thrombin time is more sensitive to the measurement of clot. Ex vivo study showed the level of hirudin in rat plasma was highest in 10 min and then it was eliminated slowly. The half-life of r-hirudin was 80~110 min depending on the assay methods. Intraveneous injection of russel viper venom was used for thrombus induction combined with vents cava ligation. Inhibition of venous thrombosis was observed with i.v. hirudin. It was dependent on the concentration of hirudin.